Oppenheimer
Oppenheimer Initiates Coverage of Sera Prognostics at Outperform
The investment bank said Sera's primary product has the potential to create a new market for blood-based testing to assess preterm birth risk.
Oppenheimer Downgrades Invitae to Perform Rating
Although Oppenheimer raised its price target from $48 to $51 in early January, the investment firm sees "increased risk of underperformance for Invitae shares."
Oppenheimer Initiates Coverage of Bionano Genomics at Outperform
The investment bank said the company's molecular diagnostics have the potential to replace microarrays for cytogenetics analysis.
Bionano Genomics to Publicly Offer Securities, Amends Loan Agreement
The genome mapping firm had fallen out of compliance with respect to its loan agreement with Innovatus and will prepay $5 million toward the loan principal.